Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.

D W Golden, S Rudra, M E Witt, T Nwizu, E E W Cohen, E Blair, K M Stenson, E E Vokes, D J Haraf

Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA. dgolden@radonc.uchicago.edu

Oral oncology 2013 Mar

filter terms:

Current standard therapy for nasopharyngeal carcinoma (NPC) is concurrent chemoradiation based on randomized data. However, limited randomized data exist to support the addition of induction chemotherapy (ICT). 58 Patients with NPC were treated from 1990 to 2010. All patients received platinum-based ICT. All 58 patients were treated with chemoradiation, 57 in a week-on/week-off (WOWO) fashion. Concurrent chemotherapy included hydroxyurea/5-fluorouracil for all patients. Median radiation dose was 70 Gy. No patient received adjuvant chemotherapy. AJCC 2009 stage was II=13, III=21, IVa=13, and IVb=11. Median follow-up for surviving patients was 66 months. Response to ICT was complete response (CR) 17% and partial response (PR) 64%. The CR rate after chemoradiation was 96%. Five-year actuarial freedom from local failure (FFLF), freedom from distant failure (FFDF), cause-specific survival (CSS), and overall survival (OS) was 98%, 90%, 90%, and 76%, respectively. Analysis of pediatric patients (n=9) demonstrated 5-year actuarial FFLF, FFDF, CSS, and OS of 100%, 88%, 80%, and 80%, respectively. ICT followed by concurrent chemoradiation demonstrates excellent FFLF, FFDF, CSS, and OS with tolerable toxicity. Induction chemotherapy followed by concurrent chemoradiation for patients with NPC should be explored further in a randomized setting. Copyright © 2012 Elsevier Ltd. All rights reserved.

Citation

D W Golden, S Rudra, M E Witt, T Nwizu, E E W Cohen, E Blair, K M Stenson, E E Vokes, D J Haraf. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral oncology. 2013 Mar;49(3):277-82